eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hyperparathyroidism |
| Comorbidity | C1561644|chronic kidney disease (ckd) |
| Sentences | 15 |
| PubMedID- 23713879 | Paricalcitol is a synthetic vitamin d2 agonist of the vdr approved for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd). |
| PubMedID- 22930877 | Secondary hyperparathyroidism in patients with chronic kidney disease (ckd) is common and usually caused by associated metabolic abnormalities, in particular, hypocalcaemia and hyperphosphataemia. |
| PubMedID- 26429172 | Vascular calcifications represent a severe complication of secondary hyperparathyroidism in patients with chronic kidney disease (ckd) stage 5. |
| PubMedID- 25984155 | Hyperphosphataemia is an established risk factor for cardiovascular mortality, renal osteodystrophy and secondary hyperparathyroidism in patients with end-stage chronic kidney disease (ckd) under renal replacement therapy. |
| PubMedID- 20090879 | The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) on dialysis. |
| PubMedID- 25949433 | This study aims to highlight the challenges in the diagnosis of hyperparathyroidism (hpt) in patients with advanced chronic kidney disease (ckd). |
| PubMedID- 22997972 | Background: secondary hyperparathyroidism develops frequently with chronic kidney disease (ckd) and is associated with poor outcome. |
| PubMedID- 25028644 | The development of calcimimetics, which are synthetic allosteric modulators of the calcium-sensing receptor (car), has been a breakthrough in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (ckd). |
| PubMedID- 20056760 | Background and objectives: the optimal treatment of secondary hyperparathyroidism in chronic kidney disease (ckd) is unknown. |
| PubMedID- 22015443 | Background: the recently developed non-invasive high-intensity focussed ultrasound (hifu) technique for the destruction of parathyroid adenomas could also be of interest for the treatment of secondary hyperparathyroidism (shp) in patients with chronic kidney disease (ckd). |
| PubMedID- 21076444 | Secondary hyperparathyroidism in chronic kidney disease (ckd) develops in response to disturbances in calcium and phosphate metabolism associated with ckd, including fgf23 and klotho. |
| PubMedID- 21885174 | Background: the efficacy of 25-hydroxyvitamin d (25[oh]d) supplementation versus vitamin d receptor activators for the treatment of secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stages 3 or 4 and vitamin d deficiency is unclear. |
| PubMedID- 25446887 | Vitamin d insufficiency is prevalent in chronic kidney disease (ckd) and associated with secondary hyperparathyroidism (shpt) and increased risk of bone and vascular disease. |
| PubMedID- 23960343 | This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (shpt) in patients with chronic kidney disease (ckd) stage 4 in a prospective clinical trial. |
| PubMedID- 23140920 | Considering its low incidence rate of long-term relapse, "presumed" total parathyroidectomy without autotrasplantation (tp) may be indicated for secondary hyperparathyroidism (2hpt) in patients with chronic kidney disease (ckd), not eligible for kidney transplantation. |
Page: 1